Piper Sandler Sticks to Their Buy Rating for Amneal Pharmaceuticals (AMRX)
In a report released today, David Amsellem from Piper Sandler maintained a Buy rating on Amneal Pharmaceuticals (AMRX – Research Report), with ...
Piper Sandler Keeps Their Hold Rating on Collegium Pharmaceutical (COLL)
Piper Sandler analyst David Amsellem maintained a Hold rating on Collegium Pharmaceutical (COLL – Research Report) today and set a price target ...
Hosted on MSN12mon
Teva upgraded to Overweight at Piper Sandler on multiple expansion
Teva Pharmaceutical (NYSE:TEVA) traded higher in the morning hours Monday after Piper Sandler upgraded ... margin recovery/ expansion. Analyst David Amsellem notes that his firm hasn't issued ...
Hosted on MSN1mon
Biogen cut to neutral at Piper Sandler on Alzheimer’s headwinds
Piper Sandler downgraded Biogen (NASDAQ ... Alzheimer's disease franchise (an uphill battle in our view)," Piper analyst David Amsellem wrote, adding, "We remain cautious on the AD franchise ...
Teva's Duvakitug Set To Shake Up IBD Treatment, Analyst Highlights Competitive Data
Piper Sandler analyst maintains an Overweight rating on Teva, citing positive feedback on duvakitug's potential in treating ...
Q4 2024 Amgen Inc Earnings Call
Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.JzBkOQ-g.js ...
Investing1mon
Piper Sandler cuts Sage Therapeutics stock price target but sees recovery in PPD sales
On Thursday, Piper Sandler analyst David Amsellem adjusted the price target for Sage Therapeutics (NASDAQ:SAGE) stock, reducing it significantly to $9 from the previous $26 while maintaining an ...
Investing1mon
Piper Sandler cuts Sage Therapeutics stock price target but sees recovery in PPD sales
On Thursday, Piper Sandler analyst David Amsellem adjusted the price target for Sage (LON:SGE) Therapeutics (NASDAQ:SAGE) stock, reducing it significantly to $9 from the previous $26 while maintaining ...